摘要
目的:分析益髓补肾方联合CHOP化疗方案对恶性淋巴瘤(malignant lymphoma,ML)患者临床疗效、免疫功能及血小板衍生生长因子(platelet derived growthfactor-BB,PDGF-BB)的影响。方法:回顾性分析2017年4月至2019年4月本院收治的92例非霍奇金淋巴瘤患者临床资料,根据治疗方式的差异分为中西医组(n=48)和对照组(n=44)。中西医组给予益髓补肾方联合CHOP化疗方案治疗,对照组给予单纯CHOP化疗方案治疗。对比两组临床疗效和安全性,比较两组治疗前后生活质量和体力状况、免疫功能指标及血清PDGF-BB水平变化情况。结果:①中西医组临床总有效率(91.67%)高于对照组(75.00%)(P<0.05)。②治疗后两组生活质量评分及KPS评分均有所上升,且中西医组生活质量和KPS评分均高于对照组(P<0.05)。③组间比较:两组治疗前免疫功能指标水平比较无统计学意义(P>0.05),治疗后两组CD3^(+)/CD8^(+)、CD4^(+)/CD8^(+)、NK细胞水平有所上升;中西医组治疗后CD3^(+)/CD8^(+)、CD4^(+)/CD8^(+)、NK细胞水平均高于对照组(P<0.05)。④治疗后,中西医组血清PDGF-BB水平低于治疗前及对照组(P<0.05)。⑤中西医组白细胞减少、周围神经损害、粒细胞减少发生率低于对照组(P<0.05),且中西医组Ⅱ°、Ⅲ°毒副发应发生率亦高于对照组(P<0.05)。结论:益髓补肾方联合CHOP化疗方案治疗可调节非霍奇金淋巴瘤患者PDGF-BB水平,改善其免疫功能,临床效果显著且安全性高,值得推广。
Objective:To analyze the effect of Yisui Bushen Prescription combined with CHOP chemotherapy on clinical efficacy,immune function and platelet derived growth factor-BB(PDGF-BB)for patients with malignant lymphoma(ML).Methods:The clinical data of 92 patients with non-Hodgkin’s lymphoma admitted to this hospital from April 2017 to April 2019 were retrospectively analyzed.According to the difference in treatment methods,they were divided into a traditional Chinese and western medicine group(n=48)and a controlled group(n=44).The traditional Chinese and western medicine group was treated with Yisui Bushen Prescription combined with CHOP chemotherapy,and the controlled group was treated with CHOP chemotherapy alone.The clinical efficacy and safety of the two groups were compared,and the changes in quality of life and physical strength,immune function indicators and serum PDGF-BB levels were compared between the two groups before and after treatment.Results:(1)The total clinical effective rate(91.67%)of the Chinese and western medicine group was higher than that of the controlled group(75.00%)(P<0.05).(2)The quality of life score and KPS score of the two groups increased after treatment,and the quality of life and KPS score of the Chinese and western medicine group were higher than those of the controlled group(P<0.05).(3)There was no statistically significant difference in the levels of immune function indexes between the two groups before treatment(P>0.05).After treatment,the levels of CD3^(+)/CD8^(+),CD4^(+)/CD8^(+),and NK cells increased in the two groups.After treatment,the levels of CD3^(+)/CD8^(+),CD4^(+)/CD8^(+)and NK cells in the traditional Chinese and western medicine group were higher than those in the controlled group(P<0.05).(4)After treatment,the serum PDGF-BB level in the Chinese and western medicine group was lower than that before treatment and lower than that in the controlled group(P<0.05).(5)The incidence of leukopenia,peripheral nerve damage,lymphopenia and granulocytopenia in the traditional Chinese and western medicine group was lower than that in the controlled group(P<0.05).Moreover,the incidence ofⅡ°andⅢ°toxic and side effect in the Chinese and western medicine group was also higher than that in the controlled group(P<0.05).Conclusion:Yisui Bushen Prescription combined with CHOP chemotherapy can regulate the PDGF-BB level of patients with non-Hodgkin’s lymphoma and improve their immune function.The clinical effect is significant and the safety is high.It is worthy of promotion.
作者
吴丹
徐玲
李慧
罗明辉
WU Dan;XU Ling;LI Hui(Department of Oncology,Dazhou Hospital of Integrated Traditional Chinese and Western Medicine,Dazhou Sichuan 635000,China;Department of Hematology,Dazhou Hospital of Integrated Traditional Chinese and Western Medicine,Dazhou Sichuan 635000,China;Department of Hematology,Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,Guangdong 518021,China)
出处
《四川中医》
2022年第4期51-55,共5页
Journal of Sichuan of Traditional Chinese Medicine
基金
四川省科技厅资助项目(编号:2017JY0153)
